Dashboard
Manage Tickers

ACLX Arcellx, Inc.

Nasdaq arcellx.com


$ 86.98 $ -1.86 (-2.09 %)    

Friday, 17-Oct-2025 15:59:56 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 86.99
$ 88.11
$ 83.05 x 10
$ 107.00 x 2
$ 86.00 - $ 90.28
$ 47.86 - $ 107.37
500,598
na
4.82B
$ 0.94
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-30-2025 10-Q
2 05-08-2025 03-31-2025 10-Q
3 02-27-2025 12-31-2024 10-K
4 11-07-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 05-09-2024 03-31-2024 10-Q
7 02-28-2024 12-31-2023 10-K
8 11-13-2023 09-30-2023 10-Q
9 08-14-2023 06-30-2023 10-Q
10 05-08-2023 03-31-2023 10-Q
11 03-29-2023 12-31-2022 10-K
12 11-14-2022 09-30-2022 10-Q
13 08-15-2022 06-30-2022 10-Q
14 05-12-2022 03-31-2022 10-Q
15 03-24-2022 12-31-2021 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

stifel-reinstates-buy-on-arcellx-announces-129-price-target
Stifel Reinstates Buy on Arcellx, Announce...
10/16/2025 13:52:28

Stifel analyst Stephen Willey reinstates Arcellx (NASDAQ:ACLX) with a Buy and announces $129 price target.

cantor-fitzgerald-assumes-arcellx-at-neutral-announces-price-target-of-88
Cantor Fitzgerald Assumes Arcellx at Neutr...
10/09/2025 13:10:53

Cantor Fitzgerald analyst Eric Schmidt assumes Arcellx (NASDAQ:ACLX) with a Neutral rating and announces Price Target of $88.

arcellx-q2-eps-094-beats-105-estimate-sales-7554m-miss-13617m-estimate
Arcellx Q2 EPS $(0.94) Beats $(1.05) Estim...
08/07/2025 20:41:58

Arcellx (NASDAQ:ACLX) reported quarterly losses of $(0.94) per share which beat the analyst consensus estimate of $(1.05) by 10...

4-analysts-assess-arcellx-what-you-need-to-know
4 Analysts Assess Arcellx: What You Need T...
07/31/2025 20:01:36

scotiabank-maintains-sector-outperform-on-arcellx-raises-price-target-to-133
Scotiabank Maintains Sector Outperform on ...
07/31/2025 17:54:11

Scotiabank analyst George Farmer maintains Arcellx (NASDAQ:ACLX) with a Sector Outperform and raises the price target from $...

fda-eases-access-to-life-saving-gene-therapies-for-blood-cancers
FDA Eases Access To Life-Saving Gene Thera...
06/30/2025 12:36:39

FDA lifts REMS for approved CAR-T therapies, easing hospital restrictions and signaling broader future access in oncology and a...

citigroup-initiates-coverage-on-arcellx-with-buy-rating-announces-price-target-of-110
Citigroup Initiates Coverage On Arcellx wi...
06/17/2025 11:39:50

Citigroup analyst Geoff Meacham initiates coverage on Arcellx (NASDAQ:ACLX) with a Buy rating and announces Price Target of ...

hc-wainwright--co-reiterates-buy-on-arcellx-maintains-115-price-target
HC Wainwright & Co. Reiterates Buy on Arce...
06/16/2025 11:34:52

HC Wainwright & Co. analyst Emily Bodnar reiterates Arcellx (NASDAQ:ACLX) with a Buy and maintains $115 price target.

dycom-industries-posts-upbeat-earnings-joins-weride-keysight-technologies-and-other-big-stocks-moving-higher-on-wednesday
Dycom Industries Posts Upbeat Earnings, Jo...
05/21/2025 14:11:45

arcellx-announces-new-data-for-its-immagine-1-study-in-patients-with-relapsed-andor-refractory-multiple-myeloma--results-from-all-117-patients-dosed-in-the-pivotal-phase-2-immagine-1-study-of-anito-cel-demonstrated-97-orr-and-68-crscr-at-a-median-follow-up-of-126-months
Arcellx Announces New Data For Its iMMagin...
05/14/2025 13:33:16

-- Results from all 117 patients dosed in the pivotal Phase 2 iMMagine-1 study of anito-cel demonstrated 97% ORR and 68% CR/sCR...

scotiabank-maintains-sector-outperform-on-arcellx-lowers-price-target-to-93
Scotiabank Maintains Sector Outperform on ...
05/09/2025 15:57:13

Scotiabank analyst George Farmer maintains Arcellx (NASDAQ:ACLX) with a Sector Outperform and lowers the price target from $...

arcellx-q1-eps-113-misses-077-estimate-sales-813m-miss-2006m-estimate
Arcellx Q1 EPS $(1.13) Misses $(0.77) Esti...
05/08/2025 20:08:05

Arcellx (NASDAQ:ACLX) reported quarterly losses of $(1.13) per share which missed the analyst consensus estimate of $(0.77) by ...

cognyte-software-posts-upbeat-results-joins-angiodynamics-allegiant-travel-and-other-big-stocks-moving-higher-on-wednesday
Cognyte Software Posts Upbeat Results, Joi...
04/02/2025 14:13:46

arcellx-fy-2024-gaap-eps-200-misses-166-estimate-sales-107936m-miss-121765m-estimate
Arcellx FY 2024 GAAP EPS $(2.00) Misses $(...
02/27/2025 21:05:51

gilead-ups-2025-outlook-eyes-lenacapavir-launch-for-hiv-prevention
Gilead Ups 2025 Outlook, Eyes Lenacapavir ...
02/12/2025 20:22:27

Gilead reported Q4 adjusted EPS of $1.90, exceeding estimates, with HIV sales up 16%. The company raised guidance and expects a...

aclx---analyzing-arcellxs-short-interest
(ACLX) - Analyzing Arcellx's Short Interest
01/14/2025 19:15:26

ubs-maintains-buy-on-arcellx-raises-price-target-to-114
UBS Maintains Buy on Arcellx, Raises Price...
12/10/2024 17:59:56

UBS analyst Ashwani Verma maintains Arcellx (NASDAQ:ACLX) with a Buy and raises the price target from $106 to $114.

hc-wainwright--co-reiterates-buy-on-arcellx-maintains-115-price-target
HC Wainwright & Co. Reiterates Buy on Arce...
12/10/2024 12:22:19

HC Wainwright & Co. analyst Emily Bodnar reiterates Arcellx (NASDAQ:ACLX) with a Buy and maintains $115 price target.

needham-reiterates-buy-on-arcellx-maintains-105-price-target
Needham Reiterates Buy on Arcellx, Maintai...
12/10/2024 10:59:58

Needham analyst Gil Blum reiterates Arcellx (NASDAQ:ACLX) with a Buy and maintains $105 price target.

in-depth-examination-of-14-analyst-recommendations-for-arcellx
In-Depth Examination Of 14 Analyst Recomme...
12/09/2024 17:00:56

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION